Market Overview:
The global endocrine system drug market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of diabetes, human growth hormone disorders, and thyroid hormone disorders across the globe. Additionally, rising awareness about these diseases and their treatment options is also contributing to the growth of this market. On the basis of type, the global endocrine system drug market can be segmented into diabetes drugs, human growth hormones (HGH), thyroid hormone disorder drugs, and others. The diabetes drugs segment is expected to account for a major share of this market in 2018 owing to its high prevalence across the globe. On the basis of application, hospitals are expected to account for a major share of this market in 2018 due to increased spending on healthcare by governments and individuals alike.
Product Definition:
Endocrine system drugs are used to treat conditions and diseases that affect the endocrine system, which is responsible for releasing hormones. These drugs can help to regulate hormone levels, which can improve symptoms associated with endocrine disorders.
Diabetes Drug:
Diabetes is a clinical condition where the inability of the pancreas to produce insulin causes decreased glucose levels in the body. Glucose level falls, an individual is said to have diabetes. There are two types of diabetes namely Type I and Type II where type I is known as insulin dependent diabetes and type II is known as non-insulin dependent diabetes.
Human Growth Hormones:
Human growth hormones (HGH), also known as somatotropin, are peptides that are produced by the pituitary gland in the brain. HGH is a protein-based hormone that controls various processes such as bone growth & repair, tissue regeneration, and cell reproduction. Growth hormone deficiency or insufficiency may result from several factors such as genetic disorders or injury to the pituitary gland which can decrease production of certain peptides including GH-I and GH-II.
Application Insights:
The hospital application segment dominated the global endocrine system drug market in 2017. This can be attributed to a large patient base and rising prevalence of chronic diseases, such as diabetes and thyroid disorders. According to data published by the WHO in 2018, around 9% of adults suffer from some form of thyroid disorder globally, with an estimated 1.3 million new cases diagnosed annually. Similarly, diabetes is a widespread disease that affects more than 20 million people across the globe and is expected to rise rapidly over the coming years due to aging population and unhealthy lifestyle habits such as excessive drinking alcohol consumption among many others. These factors are anticipated to drive demand for ESD drugs at hospitals during upcoming years.
Regional Analysis:
North America dominated the global endocrine system drug market in 2017. The presence of key players, favorable reimbursement policies, and increasing prevalence of target diseases are some factors responsible for its large share. In addition, the high adoption rate of new technologies and a well-developed healthcare infrastructure are also contributing to its large share.
Asia Pacific is expected to grow at a lucrative rate during the forecast period owing to an increase in awareness about endocrine disorders coupled with rising disposable income and improving healthcare facilities & infrastructure especially in developing countries such as China & India which is anticipated to boost growth over next eight years. Moreover, growing medical tourism industry due to affordable treatment costs will also contribute towards this growth over next eight years.
Growth Factors:
- Increasing incidence of endocrine system disorders
- Growing demand for better and more effective treatments
- Rising awareness about available treatment options
- Technological advancements in the field of endocrine system drugs
- increasing prevalence of lifestyle diseases
Scope Of The Report
Report Attributes
Report Details
Report Title
Endocrine System Drug Market Research Report
By Type
Diabetes Drug, Human Growth Hormones, Thyroid Hormone Disorder Drugs, Others
By Application
Hospital, Clinic, Medical Center, Others
By Companies
Novo Nordisk, Sanofi, Merck, Eli Lilly, AstraZeneca, AbbVie
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Endocrine System Drug Market Report Segments:
The global Endocrine System Drug market is segmented on the basis of:
Types
Diabetes Drug, Human Growth Hormones, Thyroid Hormone Disorder Drugs, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Medical Center, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novo Nordisk
- Sanofi
- Merck
- Eli Lilly
- AstraZeneca
- AbbVie
Highlights of The Endocrine System Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Diabetes Drug
- Human Growth Hormones
- Thyroid Hormone Disorder Drugs
- Others
- By Application:
- Hospital
- Clinic
- Medical Center
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Endocrine System Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Endocrine system drugs are medications that affect the endocrine system. This includes the glands and organs that produce hormones, which regulate many aspects of our body's function.
Some of the major players in the endocrine system drug market are Novo Nordisk, Sanofi, Merck, Eli Lilly, AstraZeneca, AbbVie.
The endocrine system drug market is expected to grow at a compound annual growth rate of 6.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Endocrine System Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Endocrine System Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Endocrine System Drug Market - Supply Chain
4.5. Global Endocrine System Drug Market Forecast
4.5.1. Endocrine System Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Endocrine System Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Endocrine System Drug Market Absolute $ Opportunity
5. Global Endocrine System Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Endocrine System Drug Market Size and Volume Forecast by Type
5.3.1. Diabetes Drug
5.3.2. Human Growth Hormones
5.3.3. Thyroid Hormone Disorder Drugs
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Endocrine System Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Endocrine System Drug Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Medical Center
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Endocrine System Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Endocrine System Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Endocrine System Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Endocrine System Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Endocrine System Drug Demand Share Forecast, 2019-2026
9. North America Endocrine System Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Endocrine System Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Endocrine System Drug Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Medical Center
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Endocrine System Drug Market Size and Volume Forecast by Type
9.7.1. Diabetes Drug
9.7.2. Human Growth Hormones
9.7.3. Thyroid Hormone Disorder Drugs
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Endocrine System Drug Demand Share Forecast, 2019-2026
10. Latin America Endocrine System Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Endocrine System Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Endocrine System Drug Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Medical Center
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Endocrine System Drug Market Size and Volume Forecast by Type
10.7.1. Diabetes Drug
10.7.2. Human Growth Hormones
10.7.3. Thyroid Hormone Disorder Drugs
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Endocrine System Drug Demand Share Forecast, 2019-2026
11. Europe Endocrine System Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Endocrine System Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Endocrine System Drug Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Medical Center
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Endocrine System Drug Market Size and Volume Forecast by Type
11.7.1. Diabetes Drug
11.7.2. Human Growth Hormones
11.7.3. Thyroid Hormone Disorder Drugs
11.7.4. thers
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Endocrine System Drug Demand Share, 2019-2026
12. Asia Pacific Endocrine System Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Endocrine System Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Endocrine System Drug Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Medical Center
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Endocrine System Drug Market Size and Volume Forecast by Type
12.7.1. Diabetes Drug
12.7.2. Human Growth Hormones
12.7.3. Thyroid Hormone Disorder Drugs
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Endocrine System Drug Demand Share, 2019-2026
13. Middle East & Africa Endocrine System Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Endocrine System Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Endocrine System Drug Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Medical Center
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Endocrine System Drug Market Size and Volume Forecast by Type
13.7.1. Diabetes Drug
13.7.2. Human Growth Hormones
13.7.3. Thyroid Hormone Disorder Drugs
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Endocrine System Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Endocrine System Drug Market: Market Share Analysis
14.2. Endocrine System Drug Distributors and Customers
14.3. Endocrine System Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novo Nordisk
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Sanofi
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Merck
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Eli Lilly
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. AstraZeneca
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. AbbVie
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
